Results 231 to 240 of about 6,459 (257)

The Risk of GLP‐1 Receptor Agonist (GLP‐1 RA) Exposure in Early Pregnancy. A Call to Action: Quantifying the Impact on Pregnancy Outcomes in the United Kingdom

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6455-6457, July 2026.
Michael Stedman, Pensee Wu, Ian Halsall, Nadia Chaudhury, Barbara McGowan, Martin B. Whyte, Akheel Syed, Adrian Heald   +7 more
wiley   +1 more source

Tirzepatide and prevention of chronic kidney disease [PDF]

CKJ: Clinical Kidney Journal, 2023
Chronic kidney disease; Diabetes mellitus; ObesityMalaltia renal crònica; Diabetis mellitus; ObesitatEnfermedad renal crónica; Diabetes mellitus; ObesidadTirzepatide is a twincretin recently approved to improve glycemic control in type 2 diabetes ...
Sol Carriazo, Maria JOSÉ Soler, Alberto Ortiz   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Tirzepatide

Hospital Pharmacy, 2022
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Danial E. Baker, Kaitlyn Walley, Terri L. Levien   +2 more
openaire   +2 more sources

Tirzepatide

JAAPA, 2023
ABSTRACT Obesity affects a large percentage of patients in the United States and is associated with increased mortality and higher healthcare costs. Newer guidelines recommend a minimum of 10% weight loss goal for patients with obesity, and medical management options fall short.
Christine G, Niedbala, Roxanne, Sprague
  +5 more sources

Tirzepatide for Lipodystrophy

Abstract Background Lipodystrophy encompasses a group of rare disorders associated with severe metabolic disease. These disorders are defined by abnormal fat distribution, with near-total (generalized lipodystrophy, GL) or partial (partial lipodystrophy, PL; i.e. familial partial lipodystrophy, FPLD)
Rasimcan Meral, Merve Celik Guler, Diarratou Kaba, Jeevitha Prativadi, Eric D Frontera, Maria Cristina Foss-Freitas, Noura Nachawi, David T Broome, Marissa Lightbourne, Rebecca J Brown, Simeon I Taylor, Elif A Oral   +11 more
openaire   +2 more sources

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

New England Journal of Medicine
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b,
Gomez Valderas, E., Horn, D.B., Das, S., Aronne, L.J., Dunn, J.P., Falcon, B.L., Lee, C.J., Glass, L.C., Senyucel, C., le Roux, C.W., Ho, W.   +10 more
exaly   +2 more sources

An Introduction to Tirzepatide

Clinical Diabetes, 2022
openaire   +2 more sources

Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4

Diabetes Care, 2023
Maciej T Malecki, Rachel L Batterham, Naveed Sattar   +2 more
exaly